Litigation Details for TAKEDA PHARMACEUTICAL COMPANY LTD. v. TORRENT PHARMACEUTICALS LTD. (D.N.J. 2017)

TAKEDA PHARMACEUTICAL COMPANY LTD. v. TORRENT PHARMACEUTICALS LTD. (D.N.J. 2017)

Docket		Date Filed	2017-05-05
Court	District Court, D. New Jersey	Date Terminated	2020-02-13
Cause	35:145 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Parties	TORRENT PHARMACEUTICALS LTD.
Patents	6,699,871; 7,304,086; 7,807,689; 8,173,663; 8,288,539; 8,900,638
Attorneys	DAVID LEIGH MOSES
Firms	Lerner David Littenberg Krumholz & Mentlik, LLP
Link to Docket	External link to docket

Details for TAKEDA PHARMACEUTICAL COMPANY LTD. v. TORRENT PHARMACEUTICALS LTD. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-05-05	1		expiration of U.S. Patent Nos. 7,807,689 (“the ’689 patent”), 8,173,663 (“the ’663 patent”), 8,288,539 (…regulations, the ’689 patent, the ’663 patent, the ’539 patent, and the ’638 patent are listed in the Orange… (“the ’539 patent”), and 8,900,638 (“the ’638 patent”) (collectively, the “patents-in- suit”). …attendant FDA regulations, the ’689 patent, the ’663 patent, and the ’539 patent are listed in the FDA publication…attendant FDA regulations, the ’689 patent, the ’663 patent, and the ’539 patent are listed in the Orange Book	External link to document
2020-02-04	126	Opinion	double patenting. 17. Claims 4 and 12 of U.S. Patent No. 7,807,689 are valid patent claims.…Torrent.”) Plaintiffs own U.S. Patent No. 7,807,689 (“the ’689 patent”), which is listed in the Orange…second patent for claims that are not patentably distinct from the claims of the first patent. It …claims in a second patent not patentably distinct from the claims of the first patent. The obviousness-type… claims 4 and 12 of the ’689 patent. A bench trial on Defendants’ patent invalidity defenses to infringement	External link to document
2021-02-16	136	Opinion - USCA	challenges to claims 4 and 12 of U.S. Patent No. 7,807,689, owned by Takeda. 1 See Takeda Pharm… or non-statutory obviousness-type double patenting. In their appeal, Appellants challenge… Torrent presents two obviousness-type double patent- ing theories using Feng’s 2 F162 …not 2 Feng refers to U.S. Patent No. 7,723,344. 3 Böhm refers…J.A. 33496–715 (“Mark 2004,” another patent reference pertaining to xan- thine-based	External link to document
2019-05-06	77		claims and counterclaims pertaining to U.S. Patent No. 8,900,638. Signed by Judge Stanley R. Chesler on 5… 13 February 2020 2:17-cv-03186 830 Patent None District Court, D. New Jersey	External link to document
2019-09-10	91	Summary Judgment	4 and 12 of Takeda’s U.S. Patent No. 7,807,689 (“the ’689 patent”) patent are not invalid; (2) making…on Validity of Claims 4 & 12 of U.S. Patent No. 7,807,689, and the Certification of Christopher J.…0159, will infringe Claims 4 and 12 of the ’689 patent; (3) making, using, offering to sell, or selling…0160, will infringe Claims 4 and 12 of the ’689 patent; (4) making, using, offering to sell, or selling…0161, will infringe Claims 4 and 12 of the ’689 patent; (5) making, using, offering to sell, or selling	External link to document
2019-09-10	93	Declaration of C. Harnett and Exhibits 1-14	and particularly type 2 diabetes. (U.S. Patent No. 6,699,871; WO2003/004498 A1, also assigned to… particularly type 2 diabetes. (See U.S. Patent No. 6,699,871 assigned to Merck.) 140…, 1998 IndAlo0001036 U.S. Patent No. 6,699,871 to Edmondson et al., Beta-Amino IndAlo0079268…14, 1998 IndAlo0001036 U.S. Patent No. 6,699,871 to Edmondson et al., Beta-Amino IndAlo0079268…689 patent, the ’539 patent, and the ’663 patent, are the WO ’420 publication/ CA ’730 patent and	External link to document